NEW YORK – AstraZeneca has selected an autologous T-regulator (Treg) cell therapy candidate from Quell Therapeutics' pipeline to advance into preclinical and clinical trials in type 1 diabetes, ...
Eight NHS cancer centers will examine tumors from patients with exceptional survival times, focusing on three aggressive cancer types.
Following this update, the company's stock price dropped more than 30 percent from market close Friday to $23.79 per share Monday morning.
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...
As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...
A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 ...
The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...
The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
The FDA has cleared the research organization's investigational new drug application, allowing it to start clinical tests of the experimental treatment DT2-SCT.
NEW YORK – The US Food and Drug Administration on Friday approved Syndax Pharmaceuticals' Revuforj (revumenib) as a treatment for adult and pediatric patients one year and older with relapsed or ...
January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback